Trials / Recruiting
RecruitingNCT07311356
Prognosis of Early-onset Anorexia Nervosa
Evalutation of the Prognosis and Quality of Life of Patients Hospitalized for Early-onset Anorexia Nervosa
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 140 (estimated)
- Sponsor
- Assistance Publique - Hôpitaux de Paris · Academic / Other
- Sex
- All
- Age
- 0 Years – 30 Years
- Healthy volunteers
- Not accepted
Summary
The AM2P study aims to evaluate the long-term prognosis and quality of life of patients with early-onset anorexia nervosa, assessed 4 to 9 years after hospitalization. Prognosis will be determined using a composite outcome measure based on questionnaire responses and health indicators, including body mass index (BMI). In addition, the study will examine the patients' overall physical condition both at the time of assessment and during the interval between their last hospitalization and the present evaluation.
Detailed description
This study includes all patients who were hospitalized at Robert Debré Hospital in Paris between 2016 and 2021 for early-onset anorexia nervosa. During follow-up interviews, participants will complete a standardized set of questionnaires assessing their mental and physical health (EDE-Q, PHQ-9, MSI-BPD, GAD-7, and SF-12). The primary outcome is the evaluation of the severity of the eating disorder, measured with the EDE-Q. Secondary outcomes will be derived from the additional questionnaires and will include body mass index (BMI), menstrual status, follow-up data, general well-being, impact of the eating disorder, hospital readmission, suicide attempts, depressive symptoms, borderline personality traits, anxiety, quality of life, educational attainment, occupational status, and treatments received. We hypothesize that approximately 50% of patients will achieve remission three years after hospitalization.
Conditions
Timeline
- Start date
- 2025-12-05
- Primary completion
- 2026-03-31
- Completion
- 2026-03-31
- First posted
- 2025-12-30
- Last updated
- 2026-02-03
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT07311356. Inclusion in this directory is not an endorsement.